Uprifosbuvir

Drug Profile

Uprifosbuvir

Alternative Names: IDX-21437; MK 3682; Next-generation uridine nucleotide prodrug inhibitor (IDX21437) - Idenix Pharmaceuticals; Uridine nucleotide analog (IDX21437) - Idenix Pharmaceuticals

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idenix Pharmaceuticals
  • Developer Merck & Co
  • Class Antivirals; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 19 Apr 2017 Pooled safety and efficacy data from the phase II CREST 1 and 2 trial in hepatitis C presented at The International Liver Congress 2017 (ILC-2017)
  • 23 Jan 2017 Chemical structure information added
  • 01 Dec 2016 Merck completes a phase-II trial in Hepatitis C (Combination therapy, Treatment-naive) in Australia, Austria, Canada, Denmark, France, Germany, Israel, Italy, Lithuania, New Zealand, Poland, Puerto Rico, Spain, Sweden, United Kingdom and USA (PO) (NCT02332707; EudraCT2014-003304-73)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top